Skip to main content
Premium Trial:

Request an Annual Quote

Repeat: May 1, 2001


“I’m particularly skeptical about the use of SNPs to determine whether someone is going to develop a disease or respond or not respond to a drug. The cost of generating SNPs is going to be very low, but the cost of generating phenotypes is going to be very high, and that’s rate limiting.”

David Martin, president and CEO of EOS Biotechnology, speaking at the BIO CEO and Investors Conference in New York City in February


The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.